CERS
- Cerus Corporation
()
Overview
Company Summary
Cerus Corporation (CERS) is a biomedical products company that focuses on developing and commercializing innovative technologies for enhancing the safety of blood transfusions. The company's primary product is the INTERCEPT Blood System, which is designed to prevent the transmission of various infectious diseases through transfusions.
The INTERCEPT Blood System utilizes a proprietary technology that targets and inactivates a wide range of pathogens, including viruses, bacteria, and parasites, thereby making donated blood safer for transfusion. This system can be applied to different blood components, such as red blood cells, platelets, and plasma.
Cerus primarily works with blood centers, hospitals, and other healthcare institutions to provide them with the required equipment, software, and consumables for implementing the INTERCEPT Blood System. The company's products are used in various blood-related applications, including transfusions for patients undergoing surgeries, cancer treatments, and organ transplants.
In addition to its primary product line, Cerus engages in research and development activities to expand the application of its technology and develop new products. The company also collaborates with other organizations and institutions to further advance its safety systems in the field of blood transfusions.
Overall, Cerus Corporation focuses on improving the safety of the blood supply chain and reducing the risk of transfusion-transmitted infections, thereby enhancing patient outcomes and saving lives.